AI Summary
Genmab disclosed positive EPCORE data for epcoritamab in first-line DLBCL. DLBCL-3 monotherapy achieved ORR 67% and CR 58% in elderly patients ineligible for anthracyclines; NHL-2 Arm 8 combining with R-mini-CHOP yielded ORR 93% and CR 86%. At EHA 2026, MRD negativity reached 92% with durable remissions, suggesting potential expansion of epcoritamab into 1L regimens.
Sentiment Rationale
Strong phase 2 results with high ORR/CR and MRD negativity in elderly DLBCL; two-trial data supports expansion; near-term catalyst from EHA data; partnership with AbbVie adds optionality.
Trading Thesis
Bullish GMAB over 6–12 months on expanded 1L DLBCL opportunity.
Market-Moving
- 1L DLBCL data strengthens epcoritamab's growth runway.
- EHA 2026 data provides near-term catalyst for GMAB stock.
- Combination data supports broader use; potential approvals in 1L settings.
- MRD negativity and durability metrics offset safety concerns.
Key Facts
- DLBCL-3: fixed-duration epcoritamab monotherapy in elderly anthracycline-ineligible; ORR 67%, CR 58%.
- NHL-2 Arm 8: epcoritamab + R-mini-CHOP; ORR 93%, CR 86%.
- Data presented at EHA 2026; 66 patients; median age 82.5; follow-up 21.9 months.
- Safety: CRS 71%, ICANS 18%; infections 68%.
Companies Mentioned
- Genmab A/S (GMAB): Core data driver; potential 1L DLBCL expansion; collaboration with AbbVie.
- AbbVie Inc. (ABBV): Co-development and commercialization partner; potential revenue upside from epcoritamab.
Industry News
Industry News; data readouts from EPCORE trials; supports Genmab's growth through epcoritamab pipeline.